Results 51 to 60 of about 299,677 (299)

Correlation of the differential expression of PIK3R1 and its spliced variant, p55α, in pan‐cancer

open access: yesMolecular Oncology, EarlyView.
PIK3R1 undergoes alternative splicing to generate the isoforms, p85α and p55α. By combining large patient datasets with laboratory experiments, we show that PIK3R1 spliced variants shape cancer behavior. While tumors lose the protective p85α isoform, p55α is overexpressed, changes linked to poorer survival and more pronounced in African American ...
Ishita Gupta   +10 more
wiley   +1 more source

Dimethyl fumarate combined with cisplatin at subcytotoxic doses sensitizes cervical cancer toward ferroptosis and apoptosis through GSH restriction and p53 (re)activation

open access: yesMolecular Oncology, EarlyView.
Dimethyl fumarate (DMF) reduces growth of HPV‐positive cervical cancer spheroids and induces ferroptosis in cervical cancer cells via blocking SLC7A11/Glutathione (GSH) axis. Combination of subcytotoxic doses of DMF and cisplatin (CDDP) further suppresses spheroid growth and drives cell death in 2D culture models.
Carolina Punziano   +6 more
wiley   +1 more source

Continuous renal replacement therapy [PDF]

open access: yes, 2012
Acute renal failure refers to sudden deterioration in biochemical and physiological functioning of kidneys and often associated with multi organ failure.
Amlani, Gulzar Salman
core   +1 more source

Continued monitoring of acute kidney injury survivors might not be necessary in those regaining an estimated glomerular filtration rate > 60 mL/min at 1 year [PDF]

open access: yes, 2017
Background. Severe acute kidney injury (AKI) among hospitalized patients often necessitates initiation of short-term dialysis. Little is known about the long-term outcome of those who recover to normal renal function.
Geddes, Colin C.   +4 more
core   +1 more source

SPossibilities of 4-Component Therapy in Renal Protection: UNIKUM Trial Results

open access: yesPočki, 2012
There are given the results of first in Ukraine experience of 4-component therapy (angiotensin II receptor blockers, β-blocker, acetylsalicylic acid, statin) — multimodal strategy under randomized study in patients with chronic renal disease.
D.D. Ivanov
doaj   +1 more source

Targeted modulation of IGFL2‐AS1 reveals its translational potential in cervical adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
Cervical adenocarcinoma patients face worse outcomes than squamous cell carcinoma counterparts despite similar treatment. The identification of IGFL2‐AS1's differential expression provides a molecular basis for distinguishing these histotypes, paving the way for personalized therapies and improved survival in vulnerable populations globally.
Ricardo Cesar Cintra   +6 more
wiley   +1 more source

Use orotic acid in the treatment of pathological conditions associated with hyperuricemia

open access: yesPočki, 2014
Hyperuricemia - a condition characterized by elevated relative to normal ranges, levels of uric acid in the blood. Among the diseases caused by hyperuricemia, most noteworthy are gout, urate nephropathy, and urolithiasis.
D.D. Ivanov, Ya.A. Dombrovskyi
doaj   +1 more source

CCDC80 suppresses high‐grade serous ovarian cancer migration via negative regulation of B7‐H3

open access: yesMolecular Oncology, EarlyView.
PAX8 is a lineage‐specific master regulator of transcription in high‐grade serous ovarian cancer (HGSC) progression. We show for the first time that PAX8 facilitates proliferation and metastasis by repressing the cell autonomous tumor suppressor CCDC80 and inducing B7‐H3 expression.
Aya Saleh   +12 more
wiley   +1 more source

Nifuratel Application in Therapy of Urinary Tract Infections

open access: yesPočki, 2014
The article examines the treatment of urinary tract infections, in particular attention was paid to antibiotic therapy. It is emphasized that the results of many studies and practical experience enable to consider group of nitrofurans, including ...
Ya.A. Dombrovskyi, D.D. Ivanov
doaj   +1 more source

Home - About - Disclaimer - Privacy